Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity

Biochemistry

Volumn 43, Issue 22, 2004, Pages 6959-6967

  Liu, Ruitian ^a   Yuan, Bin ^a   Emadi, Sharareh ^a   Zameer, Andleeb ^a   Schulz, Philip ^a   McAllister, Chad ^b   Lyubchenko, Yuri ^b   Goud, Gaddam ^c   Sierks, Michael R ^a  

^a Arizona State University   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLOMERATION; ANTIBODIES; BIOSENSORS; DISEASES; FLUORESCENCE; IMMUNIZATION; NEUROLOGY; PATHOLOGY; PATIENT TREATMENT; SURFACE PLASMON RESONANCE; TOXICITY;

ALZHEIMER DISEASE (AD); BINDING AFFINITIES;

BIOCHEMISTRY;

AMYLOID BETA PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING KINETICS; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICROSCOPY, ATOMIC FORCE; NEUROBLASTOMA; NEURONS; PEPTIDE LIBRARY; SENILE PLAQUES; SURFACE PLASMON RESONANCE; THIAZOLES; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 2642578354     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi049933o     Document Type: Article

References (81)

1. Klein, W. L., Krafft, G. A., and Finch, C. E. (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?, Trends Neurosci. 24, 219-224.
2. Koo, E. H., Lansbury, P. T., Jr., and Kelly, J. W. (1999) Amyloid diseases: abnormal protein aggregation in neurodegeneration, Proc. Natl. Acad. Sci. U.S.A. 96, 9989-9990.
3. Selkoe, D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease, Nature 399, A23-A31.
4. Caughey, B., and Lansbury, P. T., Jr. (2003) Protofibrils, Pores, Fibrils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders, Annu. Rev. Neurosci.
5. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates, J. Biol. Chem. 274, 25945-25952.
6. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations, Nature 418, 291.
7. Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., Naslund, J., and Lannfelt, L. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation, Nat. Neurosci. 4, 887-893.
8. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300, 486-489.
9. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., and Golde, T. E. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J. Clin. Invest. 112, 440-449.
10. Esler, W. P., and Wolfe, M. S. (2001) A portrait of Alzheimer secretases-new features and familiar faces, Science 293, 1449-1454.
11. Dewachter, I., and Van Leuven, F. (2002) Secretases as targets for the treatment of Alzheimer's disease: the prospects, Lancet Neurol. 1, 409-416.
12. Lemere, C. A., Spooner, E. T., LaFrancois, J., Malester, B., Mori, C., Leverone, J. F., Matsuoka, Y., Taylor, J. W., DeMattos, R. B., Holtzman, D. M., Clements, J. D., Selkoe, D. J., and Duff, K. E. (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice, Neurobiol. Dis. 14, 10-18.
13. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nat. Med. 6, 916-919.
14. LeVine, H. (2002) The challenge of inhibiting Abeta polymerization, Curr. Med. Chem. 9, 1121-1133.
15. Du, Y., Wei, X., Dodel, R., Sommer, N., Hampel, H., Gao, F., Ma, Z., Zhao, L., Oertel, W. H., and Farlow, M. (2003) Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity, Brain 126, 1935-1939.
16. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature 400, 173-177.
17. Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., Morgan, D., and Gordon, M. N. (2002) Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal antiinflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice, J. Neurosci. 22, 2246-2254.
18. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000) Statins and the risk of dementia, Lancet 356, 1627-1631.
19. Solomon, B., Koppel, R., Frankel, D., and Hanan-Aharon, E. (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb, Proc. Natl. Acad. Sci. U.S.A. 94, 4109-4112.
20. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G. W. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature 408, 982-985.
21. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St. George-Hyslop, P., and Westaway, D. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature 408, 979-982.
22. Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, C., Lee, M., Motter, R., Nguyen, M., Reed, A., Schenk, D., Tang, P., Vasquez, N., Seubert, P., and Yednock, T. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology, Proc. Natl. Acad. Sci. U.S.A. 100, 2023-2028.
23. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855.
24. Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., and Morgan, D. (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation, J. Neurosci. 23, 3745-3751.
25. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model, Nat. Neurosci. 5, 452-457.
26. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., and Ashe, K. H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease, J. Neurosci. 22, 6331-6335.
27. Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Muller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., Wollmer, M. A., Umbricht, D., de Quervain, D. J., Hofmann, M., Maddalena, A., Papassotiropoulos, A., and Nitsch, R. M. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease, Neuron 38, 547-554.
28. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease, Science 295, 2264-2267.
29. Lee, V. M. (2001) Abeta immunization: moving Abeta peptide from brain to blood, Proc. Natl. Acad. Sci. U.S.A. 98, 8931-8932.
30. Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jackel, S., Wei, X., Buerger, K., Hoft, C., Hemmer, B., Moller, H. J., Farlow, M., Oertel, W. H., Sommer, N., and Du, Y. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease, Ann. Neurol. 52, 253-256.
31. Matsuoka, Y., Saito, M., LaFrancois, J., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., Lemere, C., and Duff, K. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid, J. Neurosci. 23, 29-33.
32. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature 373, 523-527.
33. Brazil, M. I., Chung, H., and Maxfield, F. R. (2000) Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia, J. Biol. Chem. 275, 16941-16947.
34. Schenk, D. (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning, Nat. Rev. Neurosci. 3, 824-828.
35. Imbimbo, B. P. (2002) Toxicity of beta-amyloid vaccination in patients with Alzheimer's disease, Ann. Neurol. 51, 794.
36. Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report, Nat. Med. 9, 448-452.
37. Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., and Jucker, M. (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy, Science 298, 1379.
38. Furlan, R., Brambilla, E., Sanvito, F., Roccatagliata, L., Olivieri, S., Bergami, A., Pluchino, S., Uccelli, A., Comi, G., and Martino, G. (2003) Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice, Brain 126, 285-291.
39. Chauhan, N. B., and Siegel, G. J. (2003) Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576, J. Neurosci. Res. 74, 142-147.
40. Frenkel, D., Katz, O., and Solomon, B. (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration, Proc. Natl. Acad. Sci. U.S.A. 97, 11455-11459.
41. Town, T., Tan, J., Sansone, N., Obregon, D., Klein, T., and Mullan, M. (2001) Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42, Neurosci. Lett. 307, 101-104.
42. Nissim, A., Hoogenboom, H. R., Tomlinson, I. M., Flynn, G., Midgley, C., Lane, D., and Winter, G. (1994) Antibody fragments from a 'single pot' phage display library as immunochemical reagents, EMBO J. 13, 692-698.
43. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage, J. Mol. Biol. 222, 581-597.
44. Carter, P., Bedouelle, H., and Winter, G. (1985) Improved oligonucleotide site-directed mutagenesis using M13 vectors, Nucleic Acids Res. 13, 4431-4443.
45. Wu, H., Goud, G. N., and Sierks, M. R. (1998) Artificial antibodies for affinity chromatography of homologous proteins: application to blood clotting proteins, Biotechnol. Prog. 14, 496-499.
46. LeVine, H., III (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution, Protein Sci. 2, 404-410.
47. Shlyakhtenko, L. S., Miloseska, L., Potaman, V. N., Sinden, R. R., and Lyubchenko, Y. L. (2003) Intersegmental interactions in supercoiled DNA: atomic force microscope study, Ultramicroscopy 97, 263-270.
48. Shlyakhtenko, L. S., Potaman, V. N., Sinden, R. R., Gall, A. A., and Lyubchenko, Y. L. (2000) Structure and dynamics of three-way DNA junctions: atomic force microscopy studies, Nucleic Acids Res. 28, 3472-3477.
49. Bustamante, C., Vesenka, J., Tang, C. L., Rees, W., Guthold, M., and Keller, R. (1992) Circular DNA molecules imaged in air by scanning force microscopy, Biochemistry 31, 22-26.
50. Lee, H. C., Yin, P. H., Lu, C. Y., Chi, C. W., and Wei, Y. H. (2000) Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells, Biochem. J. 348 (Part 2), 425-432.
51. Shearman, M. S., Hawtin, S. R., and Tailor, V. J. (1995) The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides, J. Neurochem. 65, 218-227.
52. Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis, J. Biol. Chem. 278, 11612-11622.
53. Shimizu, T., Fukuda, H., Murayama, S., Izumiyama, N., and Shirasawa, T. (2002) Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease, J. Neurosci. Res. 70, 451-461.
54. Gorman, P. M., Yip, C. M., Fraser, P. E., and Chakrabartty, A. (2003) Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH, J. Mol. Biol. 325, 743-757.
55. Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T. (1997) Observation of metastable Abeta amyloid protofibrils by atomic force microscopy, Chem. Biol. 4, 119-125.
56. Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T., Jr. (1999) Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease, Biochemistry 38, 8972-8980.
57. Nichols, M. R., Moss, M. A., Reed, D. K., Lin, W. L., Mukhopadhyay, R., Hoh, J. H., and Rosenberry, T. L. (2002) Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy, Biochemistry 41, 6115-6127.
58. Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., and Klein, W. L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies, J. Neurochem. 79, 595-605.
59. Spooner, E. T., Desai, R. V., Mori, C., Leverone, J. F., and Lemere, C. A. (2002) The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol, Vaccine 21, 290-297.
60. Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh, S., Hancock, W. W., and Selkoe, D. J. (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease, Ann. Neurol. 48, 567-579.
61. Mohajeri, M. H., Saini, K., Schultz, J. G., Wollmer, M. A., Hock, C., and Nitsch, R. M. (2002) Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation, J. Biol. Chem. 277, 33012-33017.
62. Senior, K. (2002) Dosing in phase II trial of Alzheimer's vaccine suspended, Lancet Neurol. 1, 3.
63. Grubeck-Loebenstein, B., Blasko, I., Marx, F. K., and Trieb, I. (2000) Immunization with beta-amyloid: could T-cell activation have a harmful effect?, Trends Neurosci. 23, 114.
64. Monsonego, A., Imitola, J., Zota, V., Oida, T., and Weiner, H. L. (2003) Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells, J. Immunol. 171, 2216-2224.
65. Rohn, T. T., Ivins, K. J., Bahr, B. A., Cotman, C. W., and Cribbs, D. H. (2000) A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis, J. Neurochem. 74, 2331-2342.
66. Rogers, J., and Shen, Y. (2000) A perspective on inflammation in Alzheimer's disease, Ann. N.Y. Acad. Sci. 924, 132-135.
67. Marx, F., Blasko, I., Zisterer, K., and Grubeck-Loebenstein, B. (1999) Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production, Exp. Gerontol. 34, 783-795.
68. Legleiter, J., Czilli, D. L., Gitter, B., DeMattos, R. B., Holtzman, D. M., and Kowalewski, T. (2004) Effect of Different Anti-Abeta Antibodies on Abeta Fibrillogenesis as Assessed by Atomic Force Microscopy, J. Mol. Biol. 335, 997-1006.
69. Takeuchi, K., Turley, S. J., Tan, E. M., and Pollard, K. M. (1995) Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity, J. Immunol. 154, 961-971.
70. Rich, R. L., and Myszka, D. G. (2003) Spying on HIV with SPR, Trends Microbiol. 11, 124-133.
71. Urani, A., Romieu, P., Roman, F. J., and Maurice, T. (2002) Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice, Behav. Brain Res. 134, 239-247.
72. Pike, C. J., Walencewicz-Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., and Cotman, C. W. (1995) Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity, J. Neurochem. 64, 253-265.
73. Balbach, J. J., Ishii, Y., Antzutkin, O. N., Leapman, R. D., Rizzo, N. W., Dyda, F., Reed, J., and Tycko, R. (2000) Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid-state NMR, Biochemistry 39, 13748-13759.
74. Ma, B., and Nussinov, R. (2002) Stabilities and conformations of Alzheimer's beta-amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects, Proc. Natl. Acad. Sci. U.S.A. 99, 14126-14131.
75. Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases, Nat. Rev. Neurosci. 4, 49-60.
76. Hiruma, H., Katakura, T., Takahashi, S., Ichikawa, T., and Kawakami, T. (2003) Glutamate and Amyloid {beta}-Protein Rapidly Inhibit Fast Axonal Transport in Cultured Rat Hippocampal Neurons by Different Mechanisms, J. Neurosci. 23, 8967-8977.
77. George, J. M., Jin, H., Woods, W. S., and Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch, Neuron 15, 361-372.
78. Solomon, B. (2001) Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease, DNA Cell Biol. 20, 697-703.
79. Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., and Hyman, B. T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy, J. Neurosci. 22, 7873-7878.
80. Das, P., Howard, V., Loosbrock, N., Dickson, D., Murphy, M. P., and Golde, T. E. (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice, J. Neurosci. 23, 8532-8538.
81. Hudson, P. J., and Kortt, A. A. (1999) High avidity scFv multimers; diabodies and triabodies, J. Immunol. Methods 231, 177-189.